Aptar数字健康与阿斯利康合作，授权用于慢性肾病检测的人工智能算法相关的帖子：Aptar Digital Health Partners with AstraZeneca to License AI Algorithms for Chronic Kidney Disease Detection Related posts:

动脉网2025-05-26

by Mark Chiang由马克·蒋Share To分享到Aptar Digital Health has entered into a licensing agreement with AstraZeneca to utilize the pharmaceutical company’s artificial intelligence (AI) algorithms for detecting...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2538310414?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-26 23:09","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2538310414","market":"us","top_or_hot":-1,"title":"Aptar数字健康与阿斯利康合作，授权用于慢性肾病检测的人工智能算法相关的帖子：Aptar Digital Health Partners with AstraZeneca to License AI Algorithms for Chronic Kidney Disease Detection Related posts:","media":"动脉网","content":"<div>\n<p>by Mark Chiang由马克·蒋Share To分享到Aptar Digital Health has entered into a licensing agreement with AstraZeneca to utilize the pharmaceutical company’s artificial intelligence (AI) algorithms for detecting...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052623120897661265&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptar数字健康与阿斯利康合作，授权用于慢性肾病检测的人工智能算法相关的帖子：Aptar Digital Health Partners with AstraZeneca to License AI Algorithms for Chronic Kidney Disease Detection Related posts:</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptar数字健康与阿斯利康合作，授权用于慢性肾病检测的人工智能算法相关的帖子：Aptar Digital Health Partners with AstraZeneca to License AI Algorithms for Chronic Kidney Disease Detection Related posts:\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-26 23:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052623120897661265&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by Mark Chiang由马克·蒋Share To分享到Aptar Digital Health has entered into a licensing agreement with AstraZeneca to utilize the pharmaceutical company’s artificial intelligence (AI) algorithms for detecting...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052623120897661265&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052623120897661265&s=b","article_id":"2538310414","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052623120897661265&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2538310414","pubTimestamp":1748272140,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"by Mark Chiang由马克·蒋Share To分享到Aptar Digital Health has entered into a licensing agreement with AstraZeneca to utilize the pharmaceutical company’s artificial intelligence  algorithms for detecting chronic kidney disease . The collaboration grants Aptar access to AstraZeneca’s AI-driven screening technology, which is designed to identify CKD in patients more efficiently..Aptar数字健康公司与阿斯利康达成了一项许可协议，利用这家制药公司的人工智能算法来检测慢性肾病。此次合作使Aptar获得了阿斯利康基于人工智能的筛查技术，该技术旨在更高效地识别患者的CKD。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","BK4126":"金属与玻璃容器","BK4585":"ETF&股票定投概念","BK4568":"美国抗疫概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","AZN":"阿斯利康","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4007":"制药","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","ATR":"Aptar"},"translate_title":"Aptar Digital Health partners with AstraZeneca to license AI algorithms for chronic kidney disease detection Related posts: Aptar Digital Health Partners with AstraZeneca to License AI Algorithms for Chronic Kidney Disease Detection Related posts:","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATR":1,"AZN":1},"content_text":"by Mark Chiang由马克·蒋Share To分享到Aptar Digital Health has entered into a licensing agreement with AstraZeneca to utilize the pharmaceutical company’s artificial intelligence (AI) algorithms for detecting chronic kidney disease (CKD). The collaboration grants Aptar access to AstraZeneca’s AI-driven screening technology, which is designed to identify CKD in patients more efficiently..Aptar数字健康公司与阿斯利康达成了一项许可协议，利用这家制药公司的人工智能（AI）算法来检测慢性肾病（CKD）。此次合作使Aptar获得了阿斯利康基于人工智能的筛查技术，该技术旨在更高效地识别患者的CKD。The agreement marks a step forward in leveraging advanced AI tools for healthcare applications. AstraZeneca’s algorithms are tailored to enhance early detection of CKD, a condition that often progresses without noticeable symptoms until it reaches advanced stages. By integrating this technology, Aptar aims to improve diagnostic capabilities and streamline the identification process for healthcare providers..该协议标志着在利用先进人工智能工具用于医疗应用方面向前迈进了一步。阿斯利康的算法旨在加强慢性肾脏病（CKD）的早期检测，这种疾病通常在无明显症状的情况下进展，直到晚期才会被发现。通过整合这项技术，阿普塔目标是提升诊断能力，并简化医疗服务提供者的识别流程。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI提供支持Source: GO-AI-ne1来源：GO-AI-ne1Date: May 23, 2025日期：2025年5月23日Related posts:相关文章:Probiotics May Reduce Negative Feelings益生菌可能减少负面情绪DrugPatentWatch: Data Analysis Could Cut Pharma Patent Litigation Costs by 50%DrugPatentWatch：数据分析可将制药专利诉讼成本降低50%DrugPatentWatch: Generic Drug Batch Testing and Facility Inspections are Key to Patient SafetyDrugPatentWatch：仿制药批次检测和设施检查是患者安全的关键CDMO Pricing Study Finds Kilogram Costs Vary Widely, Ranging From $10 to $50.CDMO定价研究发现，千克成本差异很大，从10美元到50美元不等。©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 版权所有。与我们合作：[email protected]电子邮件地址Author作者Mark Chiang蒋志光Related Post相关内容News Flash新闻快讯46 Percent of Advanced Liver Cancer Patients Achieve Long-Term Remission with Combined LRT-IO Therapy46%的晚期肝癌患者通过联合LRT-IO疗法实现长期缓解2025-05-262025年5月26日","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2538310414","isCrawlerRequest":true}